These data provide additional understanding of the mature B cell response to melanoma by evaluating antibodies derived from circulating B cells of cancer patients. The prevalence of mature humoral responses against cancer cells in patients, as well as the capacity of a patient-derived antibody to activate effector cells against melanoma cells indicate the potential functional significance of the humoral immune response against cancer.